-

Labcorp Opens New Laboratory in South Bend, Expanding Services and Access in the Midwest

Facility to Offer Higher Levels of Service for Patients and Physicians

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the opening of a new diagnostics laboratory in South Bend, Indiana, allowing the company to enhance service levels and offerings to patients and physicians in South Bend and throughout the region.

The approximately 25,000-square-foot facility features expanded capabilities and new equipment for performing high-quality and efficient testing—creating more robust lab offerings for the community. The laboratory, which currently employs 100 individuals, will include STAT testing to expedite results for high-priority tests.

“This new lab offers increased capabilities for microbiology testing, allowing for a more flexible test menu that is tailored to fit the needs of our providers,” said Amy Rhine-Pallas, senior vice president of Labcorp’s North Central Division. “Ultimately, this leads to better patient diagnoses and outcomes. Our goal is to continue to invest in and provide the highest-quality service to patients and health care providers across the Midwest.”

Labcorp acquired the diagnostic clinical laboratory testing business of South Bend Medical Foundation in October 2019, considerably enhancing the scope of local services Labcorp offers to hospitals, physicians and patients across parts of Indiana, Michigan, Ohio and Illinois. The new laboratory further expands services to include northwestern Indiana and southern Michigan, and provides the communities in these areas with increased access and more efficient diagnostic testing solutions. In addition, the laboratory underscores Labcorp’s commitment to Indiana and builds on its strong operating presence in the state, which includes Labcorp Drug Development’s central laboratory and other facilities in Indianapolis. Labcorp currently has a number of open positions at the South Bend facility. To apply for one of these jobs, please visit: http://www.labcorp.com/careers.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

Contacts

Media: Michele Mazur – 336-436-8263
Media@Labcorp.com

Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com

LABORATORY CORPORATION OF AMERICA HOLDINGS

NYSE:LH
Details
Headquarters: Burlington, NC
CEO: Adam Schechter
Employees: 75,000
Organization: PUB
Revenues: $16.1 billion (2021)
Net Income: $2.37 billion (2021)

Release Versions

Contacts

Media: Michele Mazur – 336-436-8263
Media@Labcorp.com

Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com

More News From LABORATORY CORPORATION OF AMERICA HOLDINGS

Ovia HealthTM Expands Digital Platform Capabilities to Include Menopause Tracking

BOSTON--(BUSINESS WIRE)--Ovia Health, a trusted digital health platform for women and families, today announced the expansion of its Ovia® app, which will now allow women to track menopause symptoms and access valuable resources and support to address the transition to menopause/perimenopause. The technology is available through Ovia’s consumer application and enterprise offerings for employers and health plans. According to the National Institute on Aging (NIA), more than 1 million women trans...

Labcorp Announces 2022 Fourth Quarter and Full-Year Results

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2022, full-year 2023 guidance. “We finished the year strong, with accelerated revenue growth in Diagnostics, continued strong underlying fundamentals in Drug Development and margin expansion,” said Adam Schechter, chairman and CEO of Labcorp. “In 2022, we also advanced our strategy with the announcement of the spin of our Clinical...

Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that the new company to be formed by the planned spin-off of its Clinical Development business will be known as Fortrea. Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global CRO that offers comprehensive drug and medical device development services. With over 19,000 people, Fortrea will provide Phase I through IV clinical trial ma...
Back to Newsroom